strong result driven pharma pharma driven specialti
larg custom exp management synergi driven mwi consult
canadian busi seem make progress toward turn around pharmedium
lash drag result management rais guidanc
improv pharma outlook non-operational metric
report better expect result pharma distribut
pharma distribut revenu y/i slightli beat consensu
oper profit y/i compar consensu
result driven strong perform specialti growth larg
custom expens management faster expect realiz smith synergi
revenu y/i slightli beat consensu
oper profit y/i compar consensu result
driven mwi record first revenu quarter consult
pharmedium lash drag pharma distribut respect
management appear make progress toward turn around busi
pharmedium consent decre final pharmedium current undergo
third-parti audit two open facil expect complet month
august result audit expect impact reopen memphi
facil note reopen memphi facil would present upsid
estim assum reopen memphi model
lash management optimist long-term outlook lash given success
renew win long-term custom particularli compar prior year
recal management previous note expect lash return growth
today comment suggest progress along nice
pleas see page report import disclosur
posit believ share trade attract multipl particularli
fundament core pharma distribut stabil also view
lead posit specialti favor addit see potenti upsid
pharmedium acceler growth segment beyond mwi
lash expect becom meaning contributor
updat strateg financi
review pharmedium
top-lin growth driven
specialti includ alliancerx
acquisit hd smith store
acquir
gross margin
ebit margin
top-lin growth high-singl digit
due greater expect growth
gm due moder
gener deflat
sg better expect due
share come lower due greater
expect share repo
top-lin growth low-singl digit
due lower brand inflat
margin closer due higher
expect gener deflat lower
expect brand inflat
sg come wors expect
share come higher due lower
expect share repo
one three largest pharmaceut distribut compani
 servic pharmaceut manufactur health care provid
pharmaceut suppli channel primarili provid drug distribut relat servic
distribut comprehens offer brand name gener pharmaceut over-the-
counter health care product home health care suppli equip wide varieti
health care provid locat throughout includ acut care hospit
health system independ chain retail pharmaci mail-ord facil physician
clinic altern site facil skill nurs assist live center
management rais adj ep guidanc due improv
oper outlook pharma distribut non-operational assumpt
compani report cowen compani
rais adj ep estim
respect also rais price target base revis
dcf analysi impli share trade adj ep estim
current multipl
million except per-shar data
cowen compani
changevariancetot cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig net incom deal-rel incom ex-discontinu average ep ex-discontinu distributiontot chang basi earn basi servicesoth chang basi earn basi cowen
million except per-shar data
cowen compani
model assumptionstermin growth depreci chang work capit valuefre free futur excess number per end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig incom cont incom deal-rel incom ex-discontinu average ep ex discontinu chang incom cont ep cont end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig own net incom deal-rel incom ex-discontinu average ep ex-discontinu chang year-over-year total incom cont ep cont cowen
million
compani report cowen compani
asset receiv net doubt expens current charg total liabil account payabl incom current equiti common paid-in earn comprehens commmon stock total stockhold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return commit capit asset averag stockhold equiti cowen
million
compani report cowen compani
income/ loss flow oper activ depreci provis loss account sale invest employe stock defer incom invest impair oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash oper acquisit properti acquisit purchas treasuri dividend common proceeds/ repay debt net increase/ decreas cash equival begin cash equival end summari oper year end septemb cowen
million
compani report cowen compani
activitiesnet loss incom discontinu incom continu adjust reconcil net incom provis loss account provis defer incom employe stock loss dispos properti equipment- impair charg equiti investment- lifo pension settlement- includ intang asset loss earli retir chang oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash provid use oper activ continu net cash provid use oper activ discontinu net cash provid use oper invest activitiescapit acquir compani net cash proce sale properti equipment- equiti proce sale business- purchas invest secur avail sale- net cash provid use invest activ continu net cash provid use invest activ discontinu ops- net cash provid use invest financ activitiesborrow revolv securit credit purchas treasuri payment premium earli retir debt- defer financ cost other- exercis warrants- exercis stock dividend common purchas cap call net cash provid use financ activ continu net cash provid use financ activ discontinu op net cash provid use financ increas cash cash cash equival begin cash equival end fiscal year end septemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ credibl
indic enter pharma suppli chain sharp unexpect declin
gener deflat less expect benefit wbad econodisc
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
